Truist lowered the firm’s price target on Option Care Health (OPCH) to $34 from $41 and keeps a Buy rating on the shares. The company’s solid Q3 results were overshadowed by cautious commentary surrounding potential Stelara profitability headwinds in 2025, the analyst tells investors in a research note. Stelara should remain a near-term overhang with improved visibility around manufacturer negotiations being key, though the firm remains bullish on the attractive demand drivers, Truist added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health price target lowered to $32 from $40 at Barrington
- Option Care Health downgraded to Hold from Buy at Jefferies
- Option Care Health Reports Q3 Revenue Surge Amid Challenges
- Option Care Health downgraded to Neutral at BofA on Stelara risks
- Option Care Health downgraded to Neutral from Buy at BofA